SWAT Team Description: Provide cross-cutting support to COVID-19 vaccine developers in the area of diagnostics, standards, assays and animal models. Co-Leads: Paul Kristiansen (CEPI) and Ivana Knezevic (WHO)

Standards & Assays  Central Lab Network  Preclinical Model Network  GISAID  Agility 

Preclinical Model Network 

About the network

• Preclinical testing network of partners with capability to handle BSL3 and/or 4 pathogens, and experience with CEPI priority pathogens: MERS, Nipah, Rift Valley Fever, Chikungunya and Lassa viruses, now also SARS-COV-2
• Includes partners who can perform high quality studies under a rigorous quality system. Research output must meet GLP or high-quality standards to generate data packages supporting submission to regulatory agencies for vaccine product development
• Perform work in alignment with UK NC3Rs guidelines. CEPI’s funding sources require CEPI to evaluate compliance with high animal ethics standards
• CEPI’s laboratory partners are located in Europe, US and Australia
• Currently testing/developing models for COVID-19 infection
• Where models are in place, preclinical vaccine testing for CEPI vaccine development partners is underway

Articles

1. Publications of model work

UK HSA:

• VMED study data
• COVID model comparison
• Preclinical model paper

CSIRO

• Preclinical model paper

WHO

• Preclinical model paper

2. Publications of vaccine testing studies

Other Texts

CEPI’s policy